why choose us

Course: Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial

CME Credits: 1.00

Released: 2021-05-24

Eight randomized clinical trials of tocilizumab for treating patients with COVID-19 have reported heterogeneous results.- Although 4 of them achieved their primary end point, improved 28-day survival was demonstrated only in the 2 largest studies and those with the highest mortality, RECOVERY and REMAP-CAP. Moreover, only RECOVERY enrolled only patients with elevated C-reactive protein (CRP) levels. The RECOVERY and REMAP-CAP trials involved a high rate of patients using dexamethasone (>80% of the patients in both treatment arms). Differences in trial outcomes may be associated with differences in power, populations, design, management, or length of follow-up.


Educational Objective
To identify the key insights or developments described in this article


View Full Course